Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, Jackisch C, Antolin S, Solbach C, Aftimos P, Huober J, Untch M, Balic M, Reinisch M, Blohmer JU, Concalves A, Rey J, Buechele T, Loibl S (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: KARGER
City/Town: BASEL
Pages Range: 30-30
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
DOI: 10.1016/j.annonc.2022.03.074
APA:
Marme, F., Hanusch, C., Furlanetto, J., Morris, P., Link, T., Denkert, C.,... Loibl, S. (2022). Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT). In ONCOLOGY RESEARCH AND TREATMENT (pp. 30-30). BASEL: KARGER.
MLA:
Marme, Frederik, et al. "Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 30-30.
BibTeX: Download